The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to have
reached 25% or more in adults. NAFLD is prevalent in obese individuals, but may also affect …

Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common
conditions that regularly co-exist and can act synergistically to drive adverse outcomes. The …

Аннотация Современная диабетология обращает самое серьезное внимание на
метаболизм жировой ткани потому, что жировая ткань очень тесно связана с …

AIM To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic
parameters of non-alcoholic steatohepatitis (NASH). METHODS Twelve patients with biopsy …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in
Western societies and a major cause of hepatic disease worldwide. Its more severe type …

There are no licensed drugs for nonalcoholic fatty liver disease (NAFLD), and there is a lack
of consensus on the best outcome measures for controlled trials. This systematic review …

Liver‐related diseases are the leading causes of death in patients with type 2 diabetes
mellitus (T2DM) in Japan. Type 2 diabetes mellitus is closely associated with non‐alcoholic …

Purpose Dipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin
hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients. A …

抄録 There are no reports regarding the efficacy of sodium-glucose cotransporter 2 inhibitor
(SGLT2i) and dipeptidyl peptidase 4 inhibitor (DPP4i) administrations in nonalcoholic fatty …

Introduction: Patients with type 2 diabetes have an increased risk of chronic liver disease
(CLD) such as non-alcoholic fatty liver disease and steatohepatitis and about one-third of …